• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Do We Help Depressed Smokers Quit?
Research Update

How Do We Help Depressed Smokers Quit?

October 1, 2024
Justin Morales, MD and Deepti Anbarasan, MD
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Justin Morales, MD, and Deepti Anbarasan, MD. Drs. Morales and Anbarasan have no financial relationships with companies related to this material.

REVIEW OF: Cinciripini PM et al, Depress Anxiety 2022;39(5):429–440

STUDY TYPE: Randomized, double-blind, placebo-controlled trial

Like many addictive and psychiatric disorders, tobacco use disorder (TUD) and depression are comorbid. People with TUD and depression have worse health outcomes and have a tougher time quitting than their counterparts without depression. In addition, smoking itself is associated with more severe depressive symptoms. To better understand the safety and efficacy of medications for smoking cessation among depressed individuals, researchers reexamined a subset of data from the landmark Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) trial (Anthenelli RM et al, Lancet 2016;387:10037:2507–2520; see CATR November 2019 for more about the EAGLES trial).

This study included 2,635 participants with clinically stable major depressive disorder (MDD) and 4,028 participants without a psychiatric disorder, dubbed the nonpsychiatric cohort (NPC); all participants in both groups smoked 10+ cigarettes daily. Overall, there were slightly more females than males (56% vs 44%), and the average age was 47. As a group, the MDD cohort had smoked longer, had made more attempts to quit, and had more psychiatric comorbidities such as anxiety or history of suicidal ideation. Subjects were randomized to receive either varenicline, bupropion, nicotine replacement therapy (NRT), or placebo for 12 weeks, along with brief smoking cessation counseling. The primary safety outcome was occurrence of psychiatric symptoms such as mood, anxiety, or psychosis, termed neuropsychiatric adverse events (NAE). The primary efficacy outcome was smoking status during the final four weeks of treatment (weeks 9–12) and at six-month follow-up. 

The safety analysis showed no difference between medications in rates of NAEs but did find that the MDD group had an overall higher rate than the NPC. Mild NAEs were common, with 41.1% of the MDD group and 29.5% of the NPC experiencing any NAEs. But they were generally tolerable, with only 1.8% of the MDD group and 0.7% of the NPC experiencing an event that was classified as serious or that led to medication discontinuation.

You might expect that bupropion, being an antidepressant, would be most effective in the MDD group, but surprisingly, that is not what researchers found. In both cohorts, varenicline worked the best, bupropion and NRT were in the middle, and placebo was the least effective. Abstinence rates were slightly lower in the MDD group vs the NPC, but this difference did not meet statistical significance (p=0.101).

Carlat Take 

This study highlights that treatments for smoking cessation are safe and effective for patients with MDD, but the “two birds with one stone” approach of using bupropion for smoking cessation in your depressed patients is not the best way to achieve abstinence. Varenicline along with behavioral counseling is your best bet, with bupropion and NRT remaining viable second-line options.

Erratum: In our last issue, we reported on recent research examining the relationship between alcohol intake and all-cause mortality. We erroneously stated that underreporting alcohol consumption would underestimate mortality risk. Instead, we should have stated that underreporting alcohol consumption would overestimate mortality risk.

Addiction Treatment
KEYWORDS bupropion major depressive disorder smoking cessation tobacco varenicline
    Justin Morales, MD

    More from this author
    Deepti Anbarasan, MD

    Are Higher-Potency Cannabis Products Riskier for Mental Illness?

    More from this author
    www.thecarlatreport.com
    Issue Date: October 1, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Stimulants, CATR, October/November/December 2024
    Overview of Stimulants
    Update on Stimulant Use Disorder
    Contingency Management for Stimulant Use Disorder
    Boost or Bust: Navigating the Risks of Prescription Stimulants
    Rapid Initiation of Extended-Release Buprenorphine
    How Do We Help Depressed Smokers Quit?
    Erratum
    CME Post-Test, Stimulants, CATR, October/November/December 2024
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.